RT Journal Article
SR Electronic
T1 Stroke Volume Reserve Is an Independent Predictor of Survival and Need for Advanced Therapies in Systolic Heart Failure Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.21.19015610
DO 10.1101/2019.12.21.19015610
A1 Ibrahim Selevany
A1 Timothy Morris
A1 Florin Vaida
A1 Eric D. Adler
A1 Barry H. Greenberg
A1 Paul J. Kim
YR 2019
UL http://medrxiv.org/content/early/2019/12/27/2019.12.21.19015610.abstract
AB Background We investigated whether stroke volume reserve (STVR) would predict 1-year mortality and need for advanced therapies in heart-failure with reduced ejection fraction (HFrEF) patients.Methods and Results We retrospectively studied 104 ambulatory patients with HFrEF (59.2±10.2 years, 89% male) referred for cardiopulmonary exercise testing (CPET). At 1 year, 39 outcomes were observed: 16 heart-transplants (HTx), 8 left ventricular assist devices (LVAD), and 15 deaths. Stroke volume (SV) was determined by the Fick principle with established values for C[a-v]O2 at rest and anaerobic threshold (AT). STVR was calculated by SVAT/SVrest. Multi-predictor regression showed a correlation of STVR≤1.3 (OR 7.92, p=0.002), cardiac index by right heart catheterization≤2 (OR 3.07, p=0.049), and peak VO2 below the 2016 ISHLT cut-off (OR 4.09, p=0.011). HFrEF patients with a low peak VO2 and STVR>1.3 showed similar survival compared to patients with a peak VO2 above the ISHLT cut-off. A scoring system was developed: STVR≤1.3—2 points, peak VO2 below the ISHLT cut-off—1 point, and cardiac index≤2—1 point. A score of ≥3 demonstrated a sensitivity of 67% and specificity of 79% for 1-year events.Conclusions STVR is a novel parameter that may better predict 1-year outcomes than peak VO2 in HFrEF patients.HighlightsPeak VO2 is used to predict outcomes in HFrEF patients.Peak VO2 correlates poorly with mortality due to many contributing factors.STVR is a novel CPET parameter that may better predict outcomes than peak VO2.Patients with adequate peak VO2 but abnormal STVR are at high risk for 1-year events.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors did not receive any payment or services related to this research projectAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in the manuscript is available and can be obtained by emailing iselevany{at}health.ucsd.edu